Skip Ribbon Commands
Skip to main content
Navigate Up
Search
Test Code
Search
Laboratory Section
Test Category
Browse By Test Name
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Lipoprotein (a), Serum (LIPA)
Test Code: LIPASO
Synonyms/Keywords
Lipoprotein (a), S
Lipoprotein a
Lp(a) apoprotein
LP "little-A"
Useful For
Cardiovascular disease (CVD) risk refinement in patients with moderate or high risk based on conventional risk factors.
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​Yes
(12-14 hours)
​Serum ​Serum Separator Tube (SST) ​Red Top Tube (RTT) ​1 mL ​0.5 mL
Collection Processing Instructions
Separate serum from red blood cells within 1 hour of collection. Aliquot specimen into a sterile plastic tube for transport.
Specimen Stability Information
Specimen Type Temperature Time
​Serum ​ ​Refrigerate (preferred) ​7 days
​Frozen ​7 days
Rejection Criteria
Gross Hemolysis
​Gross Lipemia
​Gross Icterus
Interference

Epidemiologic studies have shown Lp(a) concentrations are lowest in non-Hispanic Caucasians, Chinese, and Japanese. Hispanics have slightly higher median Lp(a) concentrations and in African Americans, the median Lp(a) serum concentration is approximately 2 times higher than in Caucasians. In most cases, the preferred test for quantifying Lp(a) is LPAWS / Lipoprotein (a) Cholesterol, Serum.

Not recommended as a screening test in the healthy population.

Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Medical Laboratories ​Monday through Saturday ​1 day Automated Turbidimetric Immunoassay
Reference Lab
Test Information

Lipoprotein (a) (Lp[a]) consists of an LDL particle that is covalently bound to an additional protein, apolipoprotein (a) (Apo[a]). Apo(a) has high-sequence homology with the coagulation factor plasminogen and, like LDL, Lp(a) contains apolipoprotein B100 (ApoB). Thus, Lp(a) is both proatherogenic and prothrombotic. Lp(a) is an independent risk factor for coronary heart disease (CHD), ischemic stroke, and aortic valve stenosis. Lp(a) has been referred to as "the most atherogenic lipoprotein." The mechanism of increased risk is unclear but most likely involves progression of atherosclerotic stenosis via intimal deposition of cholesterol and promotion of thrombosis via homology to plasminogen.

Concentrations of Lp(a) particles in the blood can be expressed readily by 2 methods: as concentrations of Lp(a) protein or as Lp(a) cholesterol. Mayo’s Cardiovascular Laboratory Medicine measures and reports Lp(a) cholesterol individually (LPAWS / Lipoprotein [a] Cholesterol, Serum) and as a part of the lipoprotein profile (LMPP / Lipoprotein Metabolism Profile). The cholesterol content of Lp(a) particles varies little, and Lp(a) can contain significant proportions of the serum cholesterol. Unlike Lp(a) cholesterol, accurate immunochemical measurement of Lp(a)-specific protein, is complicated by the heterogeneity of Lp(a) molecular size. Due to the large number of polymorphisms in the population any given individual can have an Apo(a) protein between 240 to 800 kDa. This heterogeneity leads to inaccuracies when results are expressed in terms of mg/dL of protein. In addition, the degree of atherogenicity of the Lp(a) particle may depend on the molecular size of the Lp(a)-specific protein.

Serum concentrations of Lp(a) are related to genetic factors, and are largely unaffected by diet, exercise and lipid-lowering pharmaceuticals. However, in a patient with additional modifiable CHD risk factors, more aggressive therapy to normalize these factors may be indicated if the Lp(a) value is also increased.

Reference Range Information
Performing Location Reference Range
​Mayo Medical Laboratories < or =30 mg/dL
 
Values >30 mg/dL may suggest increased risk of coronary heart disease.
Interpretation

The frequency distribution of serum lipoprotein (a) (Lp[a]) concentrations is markedly skewed toward the low end, with approximately 85% of the population having concentrations <30 mg/dL.

Lp(a) concentrations >30 mg/dL are associated with 2- to 3-fold increased risk of cardiovascular events independent of conventional risk markers.

 

Interference:

Epidemiologic studies have shown Lp(a) concentrations are lowest in non-Hispanic Caucasians, Chinese, and Japanese. Hispanics have slightly higher median Lp(a) concentrations and in African Americans, the median Lp(a) serum concentration is approximately 2 times higher than in Caucasians. In most cases, the preferred test for quantifying Lp(a) is LPAWS / Lipoprotein (a) Cholesterol, Serum.

Not recommended as a screening test in the healthy population.

Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​83695 ​1
Synonyms/Keywords
Lipoprotein (a), S
Lipoprotein a
Lp(a) apoprotein
LP "little-A"
Ordering Applications
Ordering Application Description
​Centricity ​Lipoprotein (a), Serum (LIPA)
​Cerner ​Lipoprotein (a), Serum (LIPA)
​COM ​Lipoprotein (a), Serum (LIPA)
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Fasting Required Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​Yes
(12-14 hours)
​Serum ​Serum Separator Tube (SST) ​Red Top Tube (RTT) ​1 mL ​0.5 mL
Collection Processing Instructions
Separate serum from red blood cells within 1 hour of collection. Aliquot specimen into a sterile plastic tube for transport.
Specimen Stability Information
Specimen Type Temperature Time
​Serum ​ ​Refrigerate (preferred) ​7 days
​Frozen ​7 days
Rejection Criteria
Gross Hemolysis
​Gross Lipemia
​Gross Icterus
Interference

Epidemiologic studies have shown Lp(a) concentrations are lowest in non-Hispanic Caucasians, Chinese, and Japanese. Hispanics have slightly higher median Lp(a) concentrations and in African Americans, the median Lp(a) serum concentration is approximately 2 times higher than in Caucasians. In most cases, the preferred test for quantifying Lp(a) is LPAWS / Lipoprotein (a) Cholesterol, Serum.

Not recommended as a screening test in the healthy population.

Useful For
Cardiovascular disease (CVD) risk refinement in patients with moderate or high risk based on conventional risk factors.
Test Information

Lipoprotein (a) (Lp[a]) consists of an LDL particle that is covalently bound to an additional protein, apolipoprotein (a) (Apo[a]). Apo(a) has high-sequence homology with the coagulation factor plasminogen and, like LDL, Lp(a) contains apolipoprotein B100 (ApoB). Thus, Lp(a) is both proatherogenic and prothrombotic. Lp(a) is an independent risk factor for coronary heart disease (CHD), ischemic stroke, and aortic valve stenosis. Lp(a) has been referred to as "the most atherogenic lipoprotein." The mechanism of increased risk is unclear but most likely involves progression of atherosclerotic stenosis via intimal deposition of cholesterol and promotion of thrombosis via homology to plasminogen.

Concentrations of Lp(a) particles in the blood can be expressed readily by 2 methods: as concentrations of Lp(a) protein or as Lp(a) cholesterol. Mayo’s Cardiovascular Laboratory Medicine measures and reports Lp(a) cholesterol individually (LPAWS / Lipoprotein [a] Cholesterol, Serum) and as a part of the lipoprotein profile (LMPP / Lipoprotein Metabolism Profile). The cholesterol content of Lp(a) particles varies little, and Lp(a) can contain significant proportions of the serum cholesterol. Unlike Lp(a) cholesterol, accurate immunochemical measurement of Lp(a)-specific protein, is complicated by the heterogeneity of Lp(a) molecular size. Due to the large number of polymorphisms in the population any given individual can have an Apo(a) protein between 240 to 800 kDa. This heterogeneity leads to inaccuracies when results are expressed in terms of mg/dL of protein. In addition, the degree of atherogenicity of the Lp(a) particle may depend on the molecular size of the Lp(a)-specific protein.

Serum concentrations of Lp(a) are related to genetic factors, and are largely unaffected by diet, exercise and lipid-lowering pharmaceuticals. However, in a patient with additional modifiable CHD risk factors, more aggressive therapy to normalize these factors may be indicated if the Lp(a) value is also increased.

Reference Range Information
Performing Location Reference Range
​Mayo Medical Laboratories < or =30 mg/dL
 
Values >30 mg/dL may suggest increased risk of coronary heart disease.
Interpretation

The frequency distribution of serum lipoprotein (a) (Lp[a]) concentrations is markedly skewed toward the low end, with approximately 85% of the population having concentrations <30 mg/dL.

Lp(a) concentrations >30 mg/dL are associated with 2- to 3-fold increased risk of cardiovascular events independent of conventional risk markers.

 

Interference:

Epidemiologic studies have shown Lp(a) concentrations are lowest in non-Hispanic Caucasians, Chinese, and Japanese. Hispanics have slightly higher median Lp(a) concentrations and in African Americans, the median Lp(a) serum concentration is approximately 2 times higher than in Caucasians. In most cases, the preferred test for quantifying Lp(a) is LPAWS / Lipoprotein (a) Cholesterol, Serum.

Not recommended as a screening test in the healthy population.

For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Analytical Time Methodology/Instrumentation
​Mayo Medical Laboratories ​Monday through Saturday ​1 day Automated Turbidimetric Immunoassay
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​83695 ​1
For most current information refer to the Marshfield Laboratory online reference manual.